Melanoma in organ transplant recipients: Clinicopathological features and outcome in 100 cases

American Journal of Transplantation

Volumn 8, Issue 9, 2008, Pages 1891-1900

  Matin, R N ^a   Mesher, D ^a   Proby, C M ^a   McGregor, J M ^a   Bouwes Bavinck, J N ^b   Del Marmol, V ^c   Euvrard, S ^d   Ferrandiz, C ^e   Geusau, A ^f   Hackethal, M ^g   Ho, W L ^h   Hofbauer, G F L ⁱ   Imko Walczuk, B ^j   Kanitakis, J ^d   Lally, A ^j   Lear, J T ^k   Lebbe, C ^l   Murphy, G M ^h   Piaserico, S ^m   Seckin, D ⁿ   Stockfleth, E ^g   Ulrich, C ^g   Wojnarowska, F T ^j   Lin, H Y ^o   Balch, C ^p   Harwood, C A ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASME HOSPITAL   (Belgium)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f Universitatsklinik fur Dermatologie   (Austria)

^g HUMBOLDT UNIVERSITY   (Germany)

^h BEAUMONT HOSPITAL   (Ireland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^l SAINT LOUIS HOSPITAL   (France)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ BASKENT UNIVERSITY   (Turkey)

^o UNIVERSITY OF ALABAMA   (United States)

^p JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Immunosuppression; Melanoma; Organ transplant recipients; Skin cancer

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; CASE-CONTROL STUDIES; EUROPE; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MELANOMA; MULTICENTER STUDIES AS TOPIC; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 49649105517     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02326.x     Document Type: Article

References (59)

1. Cancer facts & figures, 2003. Atlanta : American Cancer Society.
2. Diffey BL. The future incidence of cutaneous melanoma within the UK. Br J Dermatol 2004 151 : 868 872.
3. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001 63 : 8 18.
4. Tucker MA, Goldstein AM. Melanoma aetiology: Where are we? Oncogene 2003 22 : 3042 3052.
5. Marret LD, King WD, Walter SD, From L. Use of host factors to identify people at high risk for cutaneous malignant melanoma. CMAJ 1992 147 : 445 453.
6. Bliss JM, Ford D, Swerdlow AJ et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case-control studies. The International Melanoma Analysis Group. Int J Cancer 1995 62 : 367 76.
7. Berwick M, Halpern A. Melanoma epidemiology. Curr Opin Oncol 1997 9 : 178 182.
8. Gruhlich AE, Bataille V, Swerdlow AJ et al. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: A case control study in New South Wales, Australia. Int J Cancer 1996 67 : 485 491.
9. Tucker MA, Halpern A, Holly EA et al. Clinically recognised dysplastic naevi. A central risk factor for cutaneous melanoma. JAMA 1997 277 : 1439 1444.
10. Newton JA, Bataille V, Griffiths K et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma. J Am Acad Dermatol 1993 29 : 989 996.
11. Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clin 1995 13 : 605 612.
12. Tucker MA, Boice JD Jr., Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone and eye in Conneticut 1935-82. Natl Cancer Inst Monogr 1985 68 : 161 189.
13. Bower CP, Lear JT, Bygrave S, Etherington D, Harvey I, Archer CB. Basal cell carcinoma and risk fo subsequent malignancies: A cancer registry-based study in Southwest England. J Am Acad Dermatol 2000 42 : 988 991.
14. Chudovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005 115 : 813 824.
15. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001 19 : 3622 3634.
16. Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999 17 : 976 983.
17. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995 181 : 193 201.
18. Grossman D, Altieri DC. Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001 20 : 3 11.
19. Gruhlich AE, Van Leeuwen MT, Folster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007 370 : 58 67.
20. Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM. Management of solid tumours in organ-transplant recipients. Lancet Oncol 2007 8 : 921 932.
21. Bouwes-Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study Transplantation. 1996 61 : 715 721.
22. Euvrard S, Kanitakis J, Pouteil-Noble C et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995 33 (2 Pt 1 222 229.
23. Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R. Clinicopathologic features of skin cancer in organ transplant recipients: A retrospective case-control series. J Am Acad Dermatol 2006 54 : 290 300.
24. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996 61 : 274 278.
25. Penn I. Transmission of cancer from organ donors. Ann Transplant 1997 2 : 7 12.
26. Stephens JK, Everson GT, Elliott CL et al. Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000 70 : 232 236.
27. Birkeland SA, Storm HH. Risk for tumour and other disease transmission by transplantation: A population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 2002 74 : 1409 1413.
28. Morris-Stiff G, Steel A, Savage P et al. Transplantation Research Group. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant 2004 4 : 44 446.
29. Elder GJ, Hersey P, Branley P. Remission of transplanted melanoma: Clinical course and tumour cell characterisation. Clin Transplant 1997 11 : 565 568.
30. Hollenbeak CS, Todd MM, Billingsley EM et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005 104 : 1962 1967.
31. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004 4 : 905 913.
32. Jensen P, Moller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000 42 2 Pt 1 307.
33. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol 2006 154 : 472 477.
34. Brown VL, Matin RN, Cerio R, Leedham-Green ME, Proby CM, Harwood CA. Melanomas in renal transplant recipients: The London experience, and invitation to participate in a European study. Br J Dermatol 2007 156 : 165 167.
35. Jain AB, Yee LD, Nalesnik MA et al. Comparative incidence of de novo non-lymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998 66 : 1193 1200.
36. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000 143 : 513 519.
37. Rigel DS, Carucci JA. Malignant melanoma: Prevention, early detection and treatment in the 21st Century. CA Cancer J Clin 2000 50 : 215 236.
38. Greene MH, Young TI, Clark WH Jr. Malignant melanoma in renal-transplant recipients. Lancet 1981 1 : 1196 1199.
39. Laing ME, Moloney FJ, Comber H, Conlon P, Murphy GM. Malignant melanoma in renal transplant recipients. Br J Dermatol 2006 155 : 857.
40. Farzad Z, McBride WH, Cochrane AJ. Immunology of melanoma. In : Lejune FJ, Chaudhuri PK, Das Gupta TK, eds. Malignant melanoma: medical and surgical management. New York : McGraw-Hill, 1994 : 27.
41. Balch CM, Soong S-J, Atkins MB et al. An evidence based staging system for cutaneous melanoma. CA Cancer J Clin 2004 54 : 131 149.
42. Luke CG, Coventry BJ, Foster-Smith EJ, Roder DM. A critical analysis of reasons for improved survival from invasive cutaneous melanoma. Cancer Causes Control 2003 14 : 871 878.
43. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003 139 : 1620 1624.
44. Halpern AC, Guerry D 4th., Elder DE et al. Dysplastic nevi as risk markers of sporadic (non-familial) melanoma. A case-control study. Arch Dermatol 1991 127 : 995 999.
45. Bataille V, Bishop JA, Sasieni P et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: A case-control study. Br J Cancer 1996 73 : 1605 1611.
46. Schlagenhauff B, Stroebel W, Ellwanger U et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: Recommendations for initial staging examinations. Cancer 1997 80 : 60 65.
47. Laveau F, Picot MC, Dereure O et al. Metastatic melanoma of unknown primary site. Ann Dermatol Venereol 2001 128 : 893 898.
48. Anbari KK, Schuchter LM, Bucky LP et al. Melanoma of unknown primary site: Presentation, treatment, and prognosis - a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 1997 79 : 1816 1821.
49. Smith CH, McGregor JM, Barker JN, Morris RW, Rigden SP, MacDonald DM. Excess melanocytic naevi in children with renal allografts. J Am Acad Dermatol 1993 28 : 51 55.
50. Szepietowski J, Wasik F, Szepietowski T, Wlodarczyk M, Sobczak-Radwan K, Czyz W. Excess benign melanocytic naevi in renal transplant recipients. Dermatology 1997 194 : 17 19.
51. Swerdlow AJ, English J, MacKie RM et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986 292 : 1555 1559.
52. Garbe C, Buttner P, Weiss J et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: Multicentre case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994 102 : 695 699.
53. Greene MH. The prevention of cutaneous malignant melanoma: High risk groups, chemoprevention, education and screening. In : Nathanson L, ed. Current research and clinical management of melanoma. Boston : Kluwer, 1993 : 103.
54. Greene AC, O'Rourke MGE. Cutaneous malignant melanoma in association with other skin cancer. J Natl Cancer Inst 1985 74 : 977.
55. Bulliard JL, De Weck D, Fisch T, Bordoni A, Levi F. Detailed site distribution of melanoma and sunlight exposure: Aetiological patterns from a Swiss series. Ann Oncol 2007 18 : 789 794.
56. Otley C, Berg D, Ulrich C et al. Reduction of immunosuppression for transplant-associated skin cancer: Expert consensus survey. Br J Dermatol 2006 154 : 395 400.
57. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy on sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004 18 : 446 449.
58. Kauffman MH, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with reduced incidence of de novo malignancies. Transplantation 2005 80 : 883 889.
59. Ismail F, Mitchell L, Casabonne D, Newton R, Proby CM, Harwood CA. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006 155 : 916 925.